No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BIOR Biora Therapeutics
- 0.6775
- +0.0139+2.09%
Close Jul 12 16:00 ET
- 0.6900
- +0.0125+1.85%
Post 19:55 ET
24.35MMarket Cap-105P/E (TTM)
0.6820High0.6610Low87.67KVolume0.6636Open0.6636Pre Close59.08KTurnover0.82%Turnover RatioLossP/E (Static)35.94MShares4.100052wk High-0.24P/B7.28MFloat Cap0.475052wk Low--Dividend TTM10.74MShs Float398.0000Historical High--Div YieldTTM3.17%Amplitude0.4750Historical Low0.6730Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Biora Therapeutics to Host Virtual KOL Event on NaviCap Targeted Oral Delivery Platform and Results From Phase 1 Clinical Trial of BT-600 on July 17, 2024
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday,
Biora Therapeutics Reports Positive Data For Trial Of BT-600 In Ulcerative Colitis
Express News | Biora Therapeutics Inc: BT-600 Was Well Tolerated and Met All Trial Objectives
Express News | Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
Express News | Biora Therapeutics-Entered Into Equity Distribution Agreement, Co May Offer & Sell From Time to Time up to $90 Mln of Shares of Co’s Common Stock
12 Health Care Stocks Moving In Monday's After-Market Session
GainersASLAN Pharma (NASDAQ:ASLN) shares moved upwards by 11.9% to $0.4 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Biora Therapeutics (NASDA
Comments
$Biora Therapeutics(BIOR.US$
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative co...
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative co...
$Biora Therapeutics(BIOR.US$ Biora Therapeutics Inc: BT-600 Was Well Tolerated and Met All Trial Objectives
$Biora Therapeutics(BIOR.US$ I was getting some legs getting getting some legs📈
1
Momentum tickers: Should still be slow paced(these are on the scanners)
BIVI(.49) I think has bottomed at .42 - Good adds here at .40s for a run to $1. Has a large gap to $1.76 which is high target. Can use the .42 as a safety for stop loss
BIOR(.70) Filed for mixed shelf offering two weeks ago, been trying to find these…HC Wainwright has $15 Target on it, don’t believe it but I do like it for gap fill to 1.08 minimum. I think this is going to get ran up and offering dropped. Should get dips t...
BIVI(.49) I think has bottomed at .42 - Good adds here at .40s for a run to $1. Has a large gap to $1.76 which is high target. Can use the .42 as a safety for stop loss
BIOR(.70) Filed for mixed shelf offering two weeks ago, been trying to find these…HC Wainwright has $15 Target on it, don’t believe it but I do like it for gap fill to 1.08 minimum. I think this is going to get ran up and offering dropped. Should get dips t...
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg